Status:
COMPLETED
Genetic Variants in Linear Localized Scleroderma
Lead Sponsor:
University Children's Hospital, Zurich
Conditions:
Morphea
Eligibility:
All Genders
5+ years
Phase:
NA
Brief Summary
The purpose of this study is to investigate the genetic architecture of Linear Localized Scleroderma (LLS) (linear morphea) by whole exome sequencing.
Detailed Description
At present the etiology of LLS is unknown, but a genetic background is suspected. Although LLS clearly classifies as a mosaic disorder, its genetics and protein machinery remain to be understood. We ...
Eligibility Criteria
Inclusion
- Male or female subjects ≥ 5 years of age with well phenotyped LLS
- Affecting their head and / or face "termed " en coup de sabre " type LLS or Hemiatrophia faciei or Parry-Romberg syndrome, with or without therapy
- Affecting any site of the body except the head or face, with or without therapy
Exclusion
- Patients with signs of systemic scleroderma
- Patients with localized scleroderma (morphea) other than the linear type ("plaque-type", "morphea profunda", "generalized morphea") Patients with diagnosed gadolinium induced scleroderma Patients with post-irradiation scleroderma Patients with missing consent
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02222038
Start Date
August 1 2014
End Date
October 31 2017
Last Update
November 10 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital, Department of Pediatric Dermatology
Zurich, Switzerland, 8032
2
University Hospital, Department of Dermatology
Zurich, Switzerland, 8091